



FIG. 1





FIG. 2





FIG. 3





FIG. 4





FIG. 5





FIG. 6





FIG. 7





FIG. 8







FIG. 9

A


Control antibody + Abeta42-FITC monomer
215 nm (antibody)
280 nm (antibody)
495 nm (Abeta-FITC)
8.12
14.41
14.42
4.0
6.0
8.0
10.0
12.0
14.0
ml

B


NI-101.11 antibody + Abeta42-FITC monomer
215 nm (antibody)
280 nm (antibody)
495 nm (Abeta-FITC)
8.36
14.42
14.43
4.0
6.0
8.0
10.0
12.0
14.0
ml

C



22C4 antibody + Abeta42-FITC monomer
215 nm (antibody)
280 nm (antibody)
495 nm (Abeta-FITC)
14.39
6.0
8.0
10.0
12.0
14.0
ml

FIG. 10A-C





FIG. 11





FIG. 12





FIG. 13





FIG. 14A-B





FIG. 15





FIG. 16A-B





FIG. 17





FIG. 18A-E




FIG. 19A-B



Microhemorrhages
cortex and hippocampus
6
5
4
3
2
1
0
wt
tg
control
NI-101.11

FIG. 20



40
30
20
10
0
fluorescence (arb. units)
Monomer
Fibrils
10 nM NI-101.11
100 nM NI-101.11
1 uM NI-101.11

FIG. 21



50
40
30
20
10
0
% FITC positive cells
0
20
40
60
80
100
antibody concentration [ug/ml]
NI-101.11
6E10
control

FIG. 22